Thymulin (FTS): Evidence, Mechanism, Dosing & Legal Status

Thymulin — originally facteur thymique serique (FTS), now defined as the zinc-bound nonapeptide pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn — is a genuine endogenous thymic hormone, not a synthetic designer peptide. It was discovered by Bach and Dardenne in 1977, and its biological activity depends entirely on a single zinc ion.12 This monograph separates what is proven in humans from what is hyped.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Thymulin is not an FDA-approved drug; it is sold as a "research chemical not for human use." Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is thymulin and how does it work?

Thymulin is a nonapeptide (nine amino acids, apo-form roughly 857 Da) produced exclusively by thymic epithelial cells. It was first isolated from porcine serum in 1977, its sequence determined that same year, and the synthetic peptide shown to be fully biologically active.124 Its single most important property is zinc dependence: the bare peptide, called apo-thymulin, is biologically inert, and activity appears only when it binds one zinc ion in a 1:1 ratio, inducing a specific three-dimensional conformation confirmed by NMR and monoclonal-antibody studies. The active metallopeptide is "zinc-thymulin."2 Because of this absolute dependence, serum thymulin activity is a sensitive biomarker of zinc status — it falls in zinc deficiency and is corrected by zinc repletion in vivo or in vitro.2

Functionally, thymulin participates in intra- and extra-thymic T-cell differentiation, inducing T-cell maturation and modulating the T-helper/T-suppressor balance; its effect on suppressor T-cells is historically the most prominent.13 Its anti-inflammatory action — best characterized in rodent CNS models — operates by suppressing microglial activation, reducing p38 MAPK phosphorylation and blocking NF-kB nuclear activation, thereby lowering IL-1-beta, IL-6 and TNF-alpha.78 No specific high-affinity human thymulin receptor has been definitively cloned, but the bidirectional neuroendocrine axis is well documented: GH, prolactin, thyroid hormones, glucocorticoids and gonadal steroids up-regulate thymulin output, while thymulin acts as a hypophysiotropic peptide stimulating pituitary hormone release.3 Native thymulin has an extremely short circulating half-life, on the order of minutes (~10 min), reflecting rapid proteolysis — the rationale that pushed researchers toward sustained-expression gene-therapy vectors.233

What is the evidence by indication?

The human-versus-preclinical separation is critical here. The only controlled human efficacy data are decades old and limited to rheumatoid arthritis (an analogue) plus one uncontrolled hair-loss pilot. The widely cited neuroinflammation, pain and asthma data are animal only.

The rheumatoid-arthritis data are the strongest. Two randomized, double-blind, placebo-controlled trials of the synthetic thymic peptide nonathymulin compared 1, 5 and 10 mg/day; 5 mg/day was optimal, giving significant global clinical improvement (56% of patients improved versus 17% on placebo, p<0.02) plus improvement on four objective parameters, with minimal adverse effects.4 An earlier open trial of native thymulin (FTS-Zn) in RA reported sequential follow-up, and in vitro work normalized the CD4/CD8 (OKT4/OKT8) ratio in 8 of 9 RA patients' lymphocytes.56 The caveats are serious: small samples, old methodology, and a modest effect; corporate development for RA (and ischaemic heart disorders) was ultimately discontinued. You can confirm the absence of any modern registered native-thymulin RA trial via a search of ClinicalTrials.gov.

Everything else is preclinical. In rats, intracerebroventricular or intraperitoneal thymulin dose-dependently reversed endotoxin-induced inflammatory hyperalgesia (100, 500 and 1000 ng i.c.v.), while having no effect on baseline pain.7 In a 21-day CFA inflammatory-pain model, thymulin reduced thermal hyperalgesia and paw edema, inhibited spinal microglial activation and p38 MAPK phosphorylation, and lowered spinal TNF-alpha and IL-6.8 A thymulin-related peptide analogue showed analgesic and anti-inflammatory effects in neuropathic-pain and brain-inflammation models.910 For asthma, a single dose of DNA-nanoparticle-compacted thymulin-analogue gene therapy prevented airway inflammation and remodeling in ovalbumin-challenged mice, with Phase I human trials flagged only as a future goal.1112 Notably, a human observational study found serum thymulin activity is normal in asthmatic children, cautioning against over-interpreting thymic-hormone deficits in asthma.13

What doses appear in the literature?

Reported strictly as information, not a protocol. In the human rheumatoid-arthritis trials, nonathymulin was given at 1, 5 or 10 mg/day, with 5 mg/day the most effective schedule, administered parenterally.4 Rodent analgesia and neuroinflammation work used 10 to 1000 ng by intracerebroventricular injection or intraperitoneal dosing in rats — not human doses and not translatable.78 The topical hair pilot used a water-based zinc-thymulin spray applied twice daily to the affected scalp.14 Because the lyophilized peptide has a serum half-life measured in minutes, exogenous protocols imply frequent dosing — the very limitation that drove researchers toward sustained-expression gene-therapy vectors instead of repeat injection.23 Critically, activity requires adequate zinc: apo-thymulin without zinc is inactive.2 There is no FDA-approved formulation, label, or validated human dosing standard for thymulin.

How safe is thymulin?

Reported adverse events have been minimal. In the RA RCTs, nonathymulin produced only minimal adverse effects, historical reviews note no known toxic effects even at high doses in early human and animal work, and the topical alopecia pilot reported no systemic effects and no scalp redness or irritation over roughly 3,300 treatment-days.4314 The theoretical risks are those of an immunomodulating peptide: over-correction of T-cell balance, immunogenicity or anti-thymulin antibody formation with parenteral use, and — because thymulin engages a hypophysiotropic axis modulating LH, ACTH, GH, prolactin and TSH — biologically plausible endocrine effects at high exposures.3 Drug interactions are not formally studied, though the hair pilot observed no interaction with concurrent topical minoxidil or minoxidil/finasteride.14 Reasonable caution applies in pregnancy and lactation, active malignancy (a sensible precaution given its proliferative and immune actions), autoimmune disease on immunomodulators, and known hypersensitivity. As with any research-chemical peptide, product-purity hazards are a real-world concern.

What is the FDA and WADA status in 2026?

Thymulin is not FDA-approved for any human indication and is not a lawful dietary supplement; vendors typically sell it labeled "for research use only — not for human consumption."1718 In October 2023 the FDA issued warning letters to peptide sellers marketing unapproved peptides as research chemicals while signaling human use.17 In late 2023 the FDA placed roughly 19 peptides in the difficult-for-compounding Category 2, and 2026 reporting describes some of those moving back toward Category 1 — but Category 1 status does not equal FDA approval.1918 Native thymulin is not among the headline named peptides in those bulk-substance actions, yet topical zinc-thymulin is nonetheless prepared by some compounding pharmacies for hair loss as an unapproved compounded preparation. This status is fluid; the current FDA 503A bulk-substance lists should be verified before relying on any compounding pathway.

For athletes, thymulin is not specifically named on the WADA 2026 Prohibited List (for example among the S2 peptide hormones).2021 However, any substance not approved for human therapeutic use by any regulator can be prohibited at all times under category S0 (Non-Approved Substances), so tested athletes should treat thymulin as potentially bannable.22 Material sold online sits outside all three legal human-use pathways — FDA-approved drug, valid compounded prescription, or IND clinical trial — so human use of research-grade peptide is not legal regardless of buyer credentials.17

Bottom line. Thymulin is a real endogenous thymic hormone with a clean, well-characterized zinc-dependent mechanism — scientifically more credible than many designer peptides — but its human efficacy evidence is thin and old, anchored to two small 1980s RA trials (graded B) and a single uncontrolled topical-hair pilot. The proven core is zinc-dependent immune-biomarker biology and a modest historical RA signal; the analgesia, neuroprotection and asthma claims are rodent-only. From a functional-medicine standpoint, the most actionable lever is correcting the upstream driver — zinc status and thymic health — rather than treating exogenous thymulin as an established therapy. Regulatory facts here are current as of June 2026 and should be re-verified, as the compounding landscape remains in flux.